FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030972912> ?p ?o ?g. }

• W3030972912 endingPage "1087" @default.
• W3030972912 startingPage "1081" @default.
• W3030972912 abstract "Objective To explore the microRNA-16 (miR-16) and nuclear-transcription factor-κB1 (NF-κB1) expressions in human brain gliomas and their correlations with cell invasion and growth of malignant gliomas SHG44,U87 and U373.Methods (1) Twenty-nine cases of human glioma tissue samples and 6 normal brain tissues,collected in our hospital from January 2000 to January 2011,were chosen in our study; quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the expressions ofmiR-16 and NF-κB1 in these tissues.(2) In vitro cultured U87,U373 and SHG44 cells were divided into blank-control group,nonsense sequence transfected group and miR-16 mimics transfected group; 48 h after the transfection,qRT-PCR was used to detect the expressions of miR-16 and NF-κB1; tmnswell assay was used to observe the cell invasion capability; 72 h after the transfection,Western blotting was employed to detect the protein expressions of NF-κB1,matrix metallopeptidase 9 (MMP-9) and MMP-2.(3) Luciferase reporter assay was used to detect the target regulating role of miR-16 in NF-κB1 gene.(4) U87 cells were used as negative control group,and U87 cells carried stably expressed miR-16 gene were implanted into intracranial and subcutaneous nude mice (U87-miR-16 group); immunofluorescence was used to detect the MMP-9 expression,and immunohistochemical staining was used to detect the protein expressions of Ki-67,NF-κ B1 and MMP-9; subcutaneous tumor volume was measured and the growth curve was drawn.Results (1) The qPCR results showed that the expression of miR-16 in human brain glioma tissues was significantly lower than that in normal brain tissues; and gradually decreased miR-16 expressions were noted in gliomas of graded Ⅰ,Ⅱ,Ⅲ and Ⅳ (P＜0.05); NF-κB1 expression in human brain glioma tissues was significantly higher than that in normal brain tissues; and gradually increased NF-κB1 expressions were noted in gliomas of graded Ⅰ,Ⅱ,Ⅲ and Ⅳ (P＜0.05).(2) As compared with those in the blank-control group and nonsense sequence transfected group,miR-16 mimics transfected group had significantly increased miR-16 expression,decreased NF-κB1 mRNA expression,decreased invasiveness,and decreased protein expressions of NF-κB1 and MMP-9 (P＜0.05).(3) Luciferase reporter assay showed that the fluorescence normalized ratio in the pMIR-NF-κB1 group was signfcaintly higher than that in the pMIR-NF-κB1+pre-miR-16 group (P＜0.05).(4) As compared with the negative control group,the U87-miR-16 group on the 24-42 d of implantation had significantly smaller volume of tumors (P＜0.05),and lower MMP9 expression,and NF-κB1,MMP-9 and Ki-67 expressions (the proliferation index of Ki-67:13.91％ and 32.98％).Conclusion MiR-16 inhibits glioma cell invasion and growth through down-mgulating NF-κB1 and MMP-9 expressions.Key words: MicroRNA-16;  Nuclear-transcription factor-κB1;  Matrix metallopeptidase 9; Glioma;  Invasion" @default.
• W3030972912 created "2020-06-05" @default.
• W3030972912 creator A5003866201 @default.
• W3030972912 creator A5039680882 @default.
• W3030972912 creator A5042271162 @default.
• W3030972912 creator A5073845618 @default.
• W3030972912 creator A5074982674 @default.
• W3030972912 creator A5090351350 @default.
• W3030972912 date "2014-11-15" @default.
• W3030972912 modified "2023-09-22" @default.
• W3030972912 title "miR-16 inhibits glioma cell invasion through regulating NF-κB1/MMP-9 signaling pathway" @default.
• W3030972912 doi "https://doi.org/10.3760/cma.j.issn.1671-8925.2014.11.001" @default.
• W3030972912 hasPublicationYear "2014" @default.
• W3030972912 type Work @default.
• W3030972912 sameAs 3030972912 @default.
• W3030972912 citedByCount "0" @default.
• W3030972912 crossrefType "journal-article" @default.
• W3030972912 hasAuthorship W3030972912A5003866201 @default.
• W3030972912 hasAuthorship W3030972912A5039680882 @default.
• W3030972912 hasAuthorship W3030972912A5042271162 @default.
• W3030972912 hasAuthorship W3030972912A5073845618 @default.
• W3030972912 hasAuthorship W3030972912A5074982674 @default.
• W3030972912 hasAuthorship W3030972912A5090351350 @default.
• W3030972912 hasConcept C104317684 @default.
• W3030972912 hasConcept C11957725 @default.
• W3030972912 hasConcept C145059251 @default.
• W3030972912 hasConcept C1491633281 @default.
• W3030972912 hasConcept C153911025 @default.
• W3030972912 hasConcept C2776415932 @default.
• W3030972912 hasConcept C2778227246 @default.
• W3030972912 hasConcept C502942594 @default.
• W3030972912 hasConcept C54009773 @default.
• W3030972912 hasConcept C54355233 @default.
• W3030972912 hasConcept C55493867 @default.
• W3030972912 hasConcept C62112901 @default.
• W3030972912 hasConcept C81885089 @default.
• W3030972912 hasConcept C85265743 @default.
• W3030972912 hasConcept C86803240 @default.
• W3030972912 hasConceptScore W3030972912C104317684 @default.
• W3030972912 hasConceptScore W3030972912C11957725 @default.
• W3030972912 hasConceptScore W3030972912C145059251 @default.
• W3030972912 hasConceptScore W3030972912C1491633281 @default.
• W3030972912 hasConceptScore W3030972912C153911025 @default.
• W3030972912 hasConceptScore W3030972912C2776415932 @default.
• W3030972912 hasConceptScore W3030972912C2778227246 @default.
• W3030972912 hasConceptScore W3030972912C502942594 @default.
• W3030972912 hasConceptScore W3030972912C54009773 @default.
• W3030972912 hasConceptScore W3030972912C54355233 @default.
• W3030972912 hasConceptScore W3030972912C55493867 @default.
• W3030972912 hasConceptScore W3030972912C62112901 @default.
• W3030972912 hasConceptScore W3030972912C81885089 @default.
• W3030972912 hasConceptScore W3030972912C85265743 @default.
• W3030972912 hasConceptScore W3030972912C86803240 @default.
• W3030972912 hasIssue "11" @default.
• W3030972912 hasLocation W30309729121 @default.
• W3030972912 hasOpenAccess W3030972912 @default.
• W3030972912 hasPrimaryLocation W30309729121 @default.
• W3030972912 hasRelatedWork W2354639837 @default.
• W3030972912 hasRelatedWork W2363304181 @default.
• W3030972912 hasRelatedWork W2744324469 @default.
• W3030972912 hasRelatedWork W2920885521 @default.
• W3030972912 hasRelatedWork W2988979613 @default.
• W3030972912 hasRelatedWork W2996656812 @default.
• W3030972912 hasRelatedWork W2996768385 @default.
• W3030972912 hasRelatedWork W2997776311 @default.
• W3030972912 hasRelatedWork W3011261601 @default.
• W3030972912 hasRelatedWork W3029823405 @default.
• W3030972912 hasRelatedWork W3030028217 @default.
• W3030972912 hasRelatedWork W3030461505 @default.
• W3030972912 hasRelatedWork W3031852250 @default.
• W3030972912 hasRelatedWork W3031941500 @default.
• W3030972912 hasRelatedWork W3032021368 @default.
• W3030972912 hasRelatedWork W3032023714 @default.
• W3030972912 hasRelatedWork W3032360444 @default.
• W3030972912 hasRelatedWork W3032759652 @default.
• W3030972912 hasRelatedWork W3080346050 @default.
• W3030972912 hasRelatedWork W3092475696 @default.
• W3030972912 hasVolume "13" @default.
• W3030972912 isParatext "false" @default.
• W3030972912 isRetracted "false" @default.
• W3030972912 magId "3030972912" @default.
• W3030972912 workType "article" @default.